Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALFA-0701: Gemtuzumab Ozogamicin with Chemotherapy in AML
NCT00927498Phase 3Completed
- Sponsor
- Acute Leukemia French Association
- Start
- Dec 2007
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (2 arms), sponsored by Acute Leukemia French Association. Primary endpoint: Event Free Survival. Started Dec 2007; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00927498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00927498.